Gleiss Lutz has advised the international healthcare group Noucor on the acquisition of HELM Pharmaceuticals.
Noucor, which is backed by MCH Private Equity and a group of local family offices, is dedicated to the development, manufacturing and commercialization of pharmaceutical products. Headquartered in Barcelona, the company operates across multiple international markets and is committed to improving people's lives through high-quality healthcare solutions. Following the acquisition, Noucor is expected to reach approximately EUR 200 million in revenue by the end of 2026.
HELM Pharmaceuticals is an established provider of finished dosage form products with a broad product portfolio and extensive expertise in regulatory approval, supply chain management and marketing.
The acquisition supports Noucor's long-term growth strategy. It also strengthens the group's capabilities across the entire pharmaceutical value chain, particularly in product development, regulatory affairs, supply chain management, commercial operations and lifecycle management.
The following Gleiss Lutz team advised Noucor, led by Dr. Martin Viciano Gofferje (partner) and Dr. Christoph Prawit Meissner (both M&A, Berlin):
Konrad Jankiewicz, Maximilian Möllmann (both M&A, Berlin), Dr. Stefan Mayer (partner), Dr. Dominik Monz (counsel), Dr. Johannes Heck (all Tax, Frankfurt), Dr. Jacob von Andreae (partner), Aylin Hoffs (counsel), Dr. Cosima Baumeister (all Public Law/Foreign Trade Law, Düsseldorf), Dr. Eva Reudelhuber (partner, Munich), Pascal Urban (Frankfurt), Felix Hostenkamp (Munich, all Banking & Finance), Dr. Enno Burk (partner, Healthcare & Life Sciences, Berlin), Dr. Alexander Molle (partner), Dr. Felizitas Casper (both IP/Tech, Berlin), Josefine Chakrabarti (counsel, Employment, Berlin), Michael P. Clever (Real Estate, Frankfurt), Dr. Manuel Klar (counsel, Data Protection, Munich).
Forward
